A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.
about
A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
A phase 1 study of buparlisib ...... wth factor-targeted therapies.
@en
type
label
A phase 1 study of buparlisib ...... wth factor-targeted therapies.
@en
prefLabel
A phase 1 study of buparlisib ...... wth factor-targeted therapies.
@en
P2093
P2860
P356
P1433
P1476
A phase 1 study of buparlisib ...... wth factor-targeted therapies.
@en
P2093
Christopher Sweeney
David F McDermott
Eliezer M Van Allen
Joaquim Bellmunt
Jonathan E Rosenberg
Lauren Harshman
Lillian Werner
Meghara Walsh
Michelle Hirsch
Rana R McKay
P2860
P304
P356
10.1002/CNCR.30056
P407
P577
2016-05-19T00:00:00Z